Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-GFRa4 in Recurrent or Metastatic Medullary Thyroid Cancer
NCT04877613Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Aug 2021
- Primary completion
- Jun 2039
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-GFRa4 cells in Medullary Thyroid Cancer (MTC) (4 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 15 years. Started Aug 2021; status: active, not recruiting.
02
Drugs
CART-GFRa4 cells
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT04877613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877613.